Differentiated thyroid carcinoma

Researchers are testing sacituzumab govitecan, an antibody-drug conjugate, in adults with advanced differentiated or anaplastic thyroid cancer that has stopped responding to radioactive iodine. The drug targets TROP-2, a protein found at high levels on these cancer cells. The tri…

This phase 2 trial tests the drug zanzalintinib given before surgery in 45 people with advanced thyroid cancer. The goal is to see if the drug can shrink tumors, making surgery more effective. Researchers will also monitor safety and side effects.

This phase III trial is for people with a specific type of thyroid cancer (BRAF V600E-mutated) that doesn't respond to radioactive iodine. It compares two treatment options: a combination of dabrafenib and trametinib versus cabozantinib alone. The goal is to see which is safer an…

This phase II trial is testing whether two drugs, cyclophosphamide and sirolimus, can help people with metastatic thyroid cancer that has stopped responding to radioactive iodine treatment. Participants take both drugs in monthly cycles, and doctors monitor tumor size and side ef…

This study tests whether giving the targeted drug selpercatinib for 6 months before standard radioactive iodine therapy can improve outcomes for children, adolescents, and young adults (ages 2-25) with a specific type of thyroid cancer linked to RET gene fusions. The goal is to s…

This study tests a new way to treat thyroid cancer that has returned or spread. It combines two types of radiation—external beam radiation and radioactive iodine—to deliver a stronger dose to tumors. The goal is to see if this combination is safe and can give a higher radiation d…

This phase 2 trial tests a drug called XL092 in 33 people with advanced thyroid cancer that has stopped responding to radioiodine therapy. XL092 works by blocking a protein that helps cancer cells grow. The study aims to see if the drug can slow or stop cancer progression.

This study compares two approaches for treating intermediate-risk thyroid cancer after surgery. One group gets radioactive iodine as a standard precaution. The other group only gets it if a blood test and scan show signs of remaining cancer. The goal is to see if the selective ap…

This study tests whether two drugs, avutometinib and defactinib, can shrink or control certain types of advanced thyroid cancer that no longer respond to standard radioactive iodine treatment. The trial enrolls 30 adults with RAF dimer-driven differentiated or anaplastic thyroid …

This study tests two drugs, sacituzumab tirumotecan and tislelizumab, in people with advanced thyroid cancer that has stopped responding to standard treatments. The goal is to see if these drugs can shrink tumors or help people live longer. About 94 adults with three types of har…

This phase 2 trial is testing whether giving the drug pembrolizumab before thyroid surgery can help the immune system attack high-risk differentiated thyroid cancer. About 25 adults with a high chance of cancer returning will receive two doses of pembrolizumab before their thyroi…

This study compares two doses of the drug lenvatinib (24 mg vs 10 mg daily) in 34 people with advanced thyroid cancer that no longer responds to radioactive iodine. The goal is to see if the lower dose causes fewer side effects while still controlling the cancer. Participants tak…

This study compares two surgical options for people with low-risk differentiated thyroid cancer: removing only part of the thyroid (hemithyroidectomy) or the entire gland (total thyroidectomy). The goal is to see if the less extensive surgery is as effective at preventing cancer …

This study looks at whether adding radiation therapy to the usual radioactive iodine treatment can help prevent thyroid cancer from coming back in people with high-risk, advanced thyroid cancer. About 124 adults who had surgery but still have some cancer left will be randomly ass…

This phase 2 trial tests whether two targeted drugs, vemurafenib and cobimetinib, can make thyroid cancer cells more responsive to radioactive iodine therapy. The study enrolls 21 adults with high-risk, BRAF-mutated thyroid cancer who have not yet received radioactive iodine. Par…

This early-phase study tests a new radioactive drug, [177Lu]Lu-AKIR001, in 15 adults with advanced solid tumors (like thyroid, head and neck, cervical, vulvar, or lung cancer) that have stopped responding to standard treatments. The main goal is to check the drug's safety and sid…

This early-stage trial tests a new radioactive drug called Af-001 in people with advanced differentiated thyroid cancer that cannot be removed by surgery or has spread. The study has two parts: first, to find the safest dose, and second, to see if multiple doses can shrink tumors…

This study tests whether the experimental drug AL2846 can slow cancer growth in people with advanced thyroid cancer that no longer responds to radioiodine or previous targeted therapy. About 144 participants will receive either AL2846 or a placebo. The main goal is to see how lon…

This study tests whether giving targeted drugs before radioactive iodine (RAI) can make thyroid cancer tumors absorb more RAI, potentially improving treatment. It includes 32 children and teens with metastatic differentiated thyroid cancer that has spread to the lungs. Researcher…

This phase 2 trial tests whether giving larotrectinib for 6 months can make thyroid cancer cells more responsive to radioactive iodine therapy. It enrolls 13 children and young adults with a specific genetic change (NTRK fusion) whose cancer has spread to the lungs. The goal is t…

This study tests whether a special PET scan using a radioactive tracer called 68Gallium-DOTATATE can better detect thyroid cancer that has spread and no longer responds to standard radioactive iodine therapy. About 54 adults with metastatic thyroid cancer will receive one injecti…

This study is testing a new type of PET/CT scan (18F-TFB) to see if it can find thyroid cancer that has come back or spread better than the current standard scan. About 24 adults with papillary or follicular thyroid cancer will get both scans to compare results. The goal is to im…

This study compares a newer type of scan (I-124 PET/CT) to the standard scan (I-123 whole body imaging) for finding thyroid cancer that has spread. About 62 people with thyroid cancer will get both scans, and researchers will see if the new scan is more accurate. The goal is to i…

This study tests a new imaging agent called F-18 TFB for PET/CT scans in people who have had surgery and radioactive iodine for differentiated thyroid cancer but still have high tumor markers. The goal is to see if F-18 TFB finds cancer lesions better than the standard FDG PET/CT…

This study tests a website designed to help thyroid cancer patients manage symptoms after radioactive iodine (RAI) treatment. About 88 adults who had RAI in the last three years will use either the new website or a standard one for four weeks. Researchers will check if the tool i…

This study tests a decision support tool that uses blood samples from the first two weeks after thyroid surgery to predict the best levothyroxine dose. Normally, dose adjustments take months of trial and error. The trial will enroll 240 patients and compare the tool's guidance to…

This study tests two ways of preparing people with advanced thyroid cancer for a special PET scan that uses a radioactive form of iodine (I-124). The goal is to see which preparation method gives better information for calculating the right dose of radiation therapy. Thirty parti…

This study aims to improve a prediction model that helps doctors know how difficult a less invasive thyroid surgery might be. Researchers will observe 300 people with thyroid cancer or benign nodules to see which factors, like age, weight, and tumor size, affect surgery difficult…

This study will compare pain levels after three different surgical methods for removing lymph nodes in the neck (lateral neck dissection) in people with thyroid cancer. The three methods are robotic surgery, endoscopic surgery, and traditional open surgery. Researchers will measu…

This study aims to create a simple tool that helps doctors predict how difficult a specific type of thyroid cancer surgery (called transoral and submental thyroidectomy) will be. Researchers will study 500 patients to find out which factors before surgery make the operation harde…

This study aims to create and test a scoring system called RTAS to evaluate how well surgeons perform robotic thyroidectomy, a surgery to remove all or part of the thyroid gland. Researchers will observe 200 participants with thyroid cancer or benign nodules who are having this s…

This study is gathering information from 100 adults with a type of thyroid cancer that no longer responds to standard radioactive iodine treatment. Doctors are using special medications called redifferentiating agents to try to make the cancer respond again. The goal is to track …

This study follows children who had radiation therapy for cancer to see how often they develop thyroid nodules or thyroid cancer. Researchers will compare them to children who did not have radiation, looking for risk factors and genetic clues. The goal is to create better screeni…

This study looks at how a 7-day low-iodine diet changes the amount of radioactive iodine taken up by the body in people who have had their thyroid removed due to thyroid cancer. Researchers will measure iodine uptake before and after the diet in 25 adults. The goal is to understa…

This study tests whether a special decision aid website helps people with intermediate-risk thyroid cancer make informed choices about radioactive iodine (RAI) treatment. About 408 participants will be randomly assigned to use either the decision aid or a standard information web…

This study tests a special collar worn around the neck that measures radiation exposure in people with thyroid cancer or Graves' disease receiving radioactive iodine therapy. The goal is to see if this device gives more accurate dosing information than current methods, potentiall…